Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)

Slides:



Advertisements
Similar presentations
K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.
Advertisements

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.
Department of Neurology, Mayo Clinic Arizona
December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
DIAN Treatment Trials An Update Sunday February 10, :00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN.
Real-Time Server Oriented Operating System for Embedded Applications David Donari, Leo Ordinez, Rodrigo Santos and J. Orozco Instituto de Investigaciones.
Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.
Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.
Clinical, cognitive and genetic predictors of conversion from amnestic mild cognitive impairment to Alzheimer’s disease in Chinese older adults (Chu LW,
Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Mechanism of Amyloid Removal in Patients With Alzheimer.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.
Arg-ADNI Gustavo E. Sevlever (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri and Arg-ADNI group. Memory and Aging Center.
DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)
ADNI PPSB Update WW ADNI Meeting 22 July, An Eventful Year… Successful renewal of ADNI (ADNI-3) PPSB had an opportunity to contribute – PPSB/Biomarker.
WISCONSIN ALZHEIMER’S DISEASE RESEARCH CENTER
Update of China-ADNI Kuncheng Li, MD. PhD.
ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue
Volume 3, Issue 4, Pages (November 2017)
INDIA - ADNI Dr Naren Rao
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Update of China-ADNI Kuncheng Li, MD. PhD.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Presenter: Dr. Patricio Chrem
Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment  Sanna-Kaisa Herukka,
Table 2. Data Sharing for (Reporting Period)
Volume 2, Issue 1, Pages (January 2016)
Imaging AD Progression Amyloid Imaging Agents.
How I treat extramedullary myeloma
Learning About PET/CT Scans:
Modifying Disease Course in Alzheimer's Disease
Early Dementia Distinguishing AD From MCI
INDIA - ADNI Dr Naren Rao
Volume 10, Issue 3, Pages (January 2015)
ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue
Blood-Based Biomarkers in the QC Program?
Update of China-ADNI Kuncheng Li, MD. PhD.
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
Ron Petersen & Paul Aisen
AAIC 2018 Biomarker Rates of Change in Autosomal Dominant Versus “Sporadic” Alzheimer Disease John C. Morris, MD On behalf of MW Weiner, L Beckett, T.
National Institute of Mental Health and Neurosciences
Presenter: Dr. Patricio Chrem
Update of China-ADNI Kuncheng Li, MD. PhD.
Treating to Target in MS
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Argentina Arg-ADNI Ezequiel Surace, PhD.
Biomarker Modeling of Alzheimer’s Disease
Memory assessment project - Surrey Downs CCG Joanna Gavins
Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,
ADNI 3 UPDATE MICHAEL WEINER.
Figure 2 A case of early-onset PSD
Columbia University Medical Center
in Younger and Older African Americans and Whites
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Presentation transcript:

Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI) Gustavo E. Sevlever , Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri (*) and Arg-ADNI group. Centro de Memoria y Envejecimiento Instituto de Investigaciones Neurológicas (FLENI) Buenos Aires, Argentina Buenos Aires, Nov 10, 2015 *speaker

Arg-ADNI Study Timeline 4 year 2,5 Month 48 2016 / 2017 Month 30 2014 / 2015 1 First Year 2013 / 2014 B Last patient / last visit Q1 2013 B First patient / first visit Q1 2012

Arg-ADNI Patients’ Flowchart Patients Followed (Baseline) Nº= 56 Month 12 Nº= 51 Patients Followed Month 30 Nº= 32/51 Patients Followed Month 48 Nº= ? Patients Screened to ADNI Nº= 108 New Patients Invited to ADNI Nº= 6 Early MCI Nº=12 Healthy Controls Nº= 15 Late MCI Nº= 16 Dementia AD Nº=13 Early MCI Nº=10 Healthy Controls Nº= 13 Late MCI Nº= 16 Dementia AD Nº=12 Early MCI Nº=6/10 Healthy Controls Nº= 10/13 Late MCI Nº= 12/16 Dementia AD Nº=4/12 Early MCI Nº=? Healthy Controls Nº= ? Late MCI Dementia AD Patients Screened at FLENI Nº= 60 Screening Failure Nº= 7 Dropout Nº= 3 2 Claustrophobia 1 Psychiatric Disease 1 Cancer 1 Adult ADHD 2 without informant 2 removed inform.cons 1 by distance/caregiver Dropout Nº= 5 2 removed inform.cons 2 Cancer 1 Institutionalized 3

Arg-ADNI Schedule 2016 Screening / Baseline Month 12 30 Month 48 % compl. Month 12 30 Month 48 Demographic data (+) 100% Clinical, NPS, NPSq Cognitive Reserve (MCI) MCI Blood APOE CSF AB42/Tau 71% MRI (3T) FDG PET Scan 95% PiB PET scan 89% Tau PET scan (AVID)

Tau tracer (PETscan) in ADNI Cohort AVID (AV 1451) Month 48 (+) ADNI cohort (51ptes) Demographic data Clinical, NPS, NPSq Cognitive Reserve (MCI) Blood APOE CSF AB42/Tau MRI (3T) FDG PET Scan PiB PET scan Tau PET scan (AVID) Tau tracer (PETscan) in ADNI Cohort AVID (AV 1451) Start-up: April 2016

National grant application (CONICET) Start-up: Nov, 2015